FACTEURS DE RISQUE
36 CANCER CONTROL FRANCOPHONE 2021
1. Burkitt D. A sarcoma involving the jaws in african children. British Journal of Surgery.
1958;46(197):218-23.
2. Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, et al. Burkitt's
lymphoma. Lancet. 31 mars 2012;379(9822):1234-44.
3. Rochford R, Moormann AM. Burkitt's Lymphoma. Curr Top Microbiol Immunol.
2015;390(Pt 1):267-85.
4. Atallah-Yunes SA, Murphy DJ, Noy A. HIV-associated Burkitt lymphoma. Lancet
Haematol. août 2020;7(8):e594-600.
5. Hämmerl L, Colombet M, Rochford R, Ogwang DM, Parkin DM. The burden of Burkitt
lymphoma in Africa. Infect Agent Cancer. 2019;14:17.
6. Ishizawa K. JSH practical guidelines for hematological malignancies, 2018: II.
Lymphoma-6. Burkitt lymphoma (BL). Int J Hematol. sept 2019;110(3):265-71.
7. Hecht JL, Aster JC. Molecular biology of Burkitt's lymphoma. J Clin Oncol. 1 nov
2000;18(21):3707-21.
8. Ramiro AR, Jankovic M, Eisenreich T, Difilippantonio S, Chen-Kiang S, Muramatsu
M, et al. AID is required for c-myc/IgH chromosome translocations in vivo. Cell.
2004;118(4):431-8.
9. Robbiani DF, Bothmer A, Callen E, Reina-San-Martin B, Dorsett Y, Difilippantonio
S, et al. AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH
translocations. Cell. 2008;135(6):1028-38.
10. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins.
Nat Rev Mol Cell Biol. août 2005;6(8):635-45.
11. Lindström MS, Wiman KG. Role of genetic and epigenetic changes in Burkitt
lymphoma. Semin Cancer Biol. oct 2002;12(5):381-7.
12. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARFMdm2-p53 tumor suppressor pathway
in Myc-induced lymphomagenesis. Genes Dev.
15 oct 1999;13(20):2658-69.
13. Kelly GL, Rickinson AB. Burkitt lymphoma: revisiting the pathogenesis of a virusassociated malignancy.
Hematology Am Soc Hematol Educ Program. 2007;277-84.
14. Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C, et al.
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.
Nature. 11 août 2005;436(7052):807-11.
15. Ferry JA. Burkitt's Lymphoma: Clinicopathologic Features and Differential Diagnosis.
The Oncologist. avr 2006;11(4):375-83.
16. Rochford R. Epstein-Barr virus infection of infants: implications of early age of
infection on viral control and risk for Burkitt lymphoma. Boletín Médico del Hospital
Infantil de México. janv 2016;73(1):41-6.
17. Henle W, Henle G. The sero-epidemiology of Epstein-Barr virus. Adv Pathobiol.
1976;(5):5-17.
18. Joncas J, Boucher J, Granger-Julien M, Filion C. Epstein-Barr virus infection in the
neonatal period and in childhood. Can Med Assoc J. 5 janv 1974;110(1):33-7.
19. Hjalgrim H, Friborg J, Melbye M. The epidemiology of EBV and its association
with malignant disease. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS,
Roizman B, Whitley R, et al., éditeurs. Human Herpesviruses: Biology, Therapy, and
Immunoprophylaxis [Internet]. Cambridge: Cambridge University Press; 2007 [cité 23
mars 2020]. Disponible sur: http://www.ncbi.nlm.nih.gov/books/NBK47424/
20. Thorley-Lawson DA. EBV the prototypical human tumor virus--just how bad is it?
J Allergy Clin Immunol. août 2005;116(2):251-61; quiz 262.
21. Germini D, Sall FB, Shmakova A, Wiels J, Dokudovskaya S, Drouet E, et al. Oncogenic
Properties of the EBV ZEBRA Protein. Cancers (Basel). 5 juin 2020;12(6).
22. Sall FB. Rôle des virus EBV et VIH dans la formation de la translocation
chromosomique t(8;14) du Lymphome de Burkitt [Thèse de Doctorat]. [FranceSénégal]: Universités
Paris-Saclay et Cheikh Anta Diop; 2021.
23. Kim JH, Kim WS, Park C. Epstein-Barr virus latent membrane protein 1 increases
genomic instability through Egr-1-mediated up-regulation of activation-induced
cytidine deaminase in B-cell lymphoma. Leuk Lymphoma. sept 2013;54(9):2035-40.
24. Lu J, Murakami M, Verma SC, Cai Q, Haldar S, Kaul R, et al. Epstein-Barr Virus nuclear
antigen 1 (EBNA1) confers resistance to apoptosis in EBV-positive B-lymphoma cells
through up-regulation of survivin. Virology. 5 févr 2011;410(1):64-75.
25. Wang R, Wang J, Zhang N, Wan Y, Liu Y, Zhang L, et al. The interaction between Vav1
and EBNA1 promotes survival of Burkitt's lymphoma cells by down-regulating the
expression of Bim. Biochem Biophys Res Commun. 16 avr 2019;511(4):787-93.
26. Zeng M, Chen Y, Jia X, Liu Y. The Anti-Apoptotic Role of EBV-LMP1 in Lymphoma
Cells. Cancer Manag Res. 2020;12:8801-11.
27. Portis T, Longnecker R. Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte
survival through constitutive activation of the Ras/PI3K/Akt pathway. Oncogene. 11 nov
2004;23(53):8619-28.
28. Hernandez-Vargas H, Gruffat H, Cros MP, Diederichs A, Sirand C, Vargas-Ayala RC,
et al. Viral driven epigenetic events alter the expression of cancer-related genes in
Epstein-Barr-virus naturally infected Burkitt lymphoma cell lines. Scientific Reports.
2017;7(1).
29. Niller HH, Banati F, Salamon D, Minarovits J. Epigenetic Alterations in Epstein-Barr
Virus-Associated Diseases. Adv Exp Med Biol. 2016;879:39-69.
30. Takacs M, Segesdi J, Banati F, Koroknai A, Wolf H, Niller HH, et al. The importance of
epigenetic alterations in the development of epstein-barr virus-related lymphomas.
Mediterr J Hematol Infect Dis. 15 nov 2009;1(2):e2009012.
31. Kalchschmidt JS, Bashford-Rogers R, Paschos K, Gillman ACT, Styles CT, Kellam P, et
al. Epstein-Barr virus nuclear protein EBNA3C directly induces expression of AID and
somatic mutations in B cells. The Journal of Experimental Medicine. 2016;jem.20160120.
32. Gruhne B, Sompallae R, Marescotti D, Kamranvar S, Gastaldello S, Masucci M. The
Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of
reactive oxygen species. Proceedings of the National Academy of Sciences of the United
States of America. 2009;106(7):2313-8.
33. Roix JJ, McQueen PG, Munson PJ, Parada LA, Misteli T. Spatial proximity of
translocation-prone gene loci in human lymphomas. Nat Genet. juill 2003;34(3):287-91.
34. Bonev B, Cavalli G. Organization and function of the 3D genome. Nature Reviews
Genetics. 2016;17(12):772-772.
35. Misteli T. Chromosome territories: The arrangement of chromosomes in the nucleus.
Nature Education. 2008;1(1):167.
36. Parada LA, McQueen PG, Misteli T. Tissue-specific spatial organization of genomes.
2004;5(7).
37. Sklyar I, Iarovaia OV, Gavrilov AA, Pichugin A, Germini D, Tsfasman T, et al. Distinct
Patterns of Colocalization of the CCND1 and CMYC Genes With Their Potential
Translocation Partner IGH at Successive Stages of B-Cell Differentiation. J Cell Biochem.
2016;117(7):1506-10.
38. Sall FB, Germini D, Kovina AP, Ribrag V, Wiels J, Toure AO, et al. Effect of
Environmental Factors on Nuclear Organization and Transformation of Human B
Lymphocytes. Biochemistry (Mosc). avr 2018;83(4):402-10.
39. Bouvard V, Baan RA, Grosse Y, Lauby-Secretan B, El Ghissassi F, Benbrahim-Tallaa
L, et al. Carcinogenicity of malaria and of some polyomaviruses. Lancet Oncol. avr
2012;13(4):339-40.
40. Carpenter LM, Newton R, Casabonne D, Ziegler J, Mbulaiteye S, Mbidde E, et al.
Antibodies against malaria and Epstein-Barr virus in childhood Burkitt lymphoma: A
case-control study in Uganda. International Journal of Cancer. 2008;122(6):1319-23.
41. Emmanuel B, Kawira E, Ogwang MD, Wabinga H, Magatti J, Nkrumah F, et al. African
Burkitt lymphoma: age-specific risk and correlations with malaria biomarkers. Am J Trop
Med Hyg. mars 2011;84(3):397-401.
42. Mutalima N, Molyneux E, Jaffe H, Kamiza S, Borgstein E, Mkandawire N, et al.
Associations between Burkitt lymphoma among children in Malawi and infection with
HIV, EBV and malaria: Results from a case-control study. PLoS ONE. 2008;3(6).
43. Kafuko GW, Burkitt DP. Burkitt's lymphoma and malaria. Int J Cancer. 15 juill
1970;6(1):1-9.
44. Guech-Ongey M, Yagi M, Palacpac NMQ, Emmanuel B, Talisuna AO, Bhatia K, et al.
Antibodies reactive to Plasmodium falciparum serine repeat antigen in children with
Burkitt lymphoma from Ghana. Int J Cancer. 15 avr 2012;130(8):1908-14.
45. Aka P, Vila MC, Jariwala A, Nkrumah F, Emmanuel B, Yagi M, et al. Endemic Burkitt
lymphoma is associated with strength and diversity of Plasmodium falciparum malaria
stage-specific antigen antibody response. Blood. 1 août 2013;122(5):629-35.
Références
Fatimata Bintou Sall, Médecin Hématologiste au Centre
Hospitalier Universitaire Aristide Le Dantec. PhD en Biologie
cellulaire et moléculaire (Université Paris Saclay) et Biologie et
Pathologies Humaines (Université Cheikh Anta Diop de Dakar).
Domaine d'intérêt de recherche : Cancers hématologiques de
l'enfant, particulièrement le lymphome de Burkitt et les mécanismes
d'oncogenèses induits par le virus EBV dans le développement de
cette pathologie.
Diego Germini, PhD en virologie et oncologie. Chercheur à
l'UMR9018 du CNRS, à l'Institut Gustave Roussy. Domaine
d'intérêt de recherche : Leucémies et Lymphomes, particulièrement
le lymphome de Burkitt et les mécanismes d'oncogènes induits par
les virus EBV et VIH.